RANOLAZINE- ranolazine tablet, extended release
Viona Pharmaceuticals Inc
Ranolazine (ra NOE la zeen)
500 mg tablets
1000 mg tablets
Read this Patient Information before you start taking ranolazine extended-release tablet and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.
What are ranolazine extended-release tablet?
Ranolazine extended-release tablet is a prescription medicine used to treat angina that keeps coming back (chronic angina).
Ranolazine extended-release tablet may be used with other medicines that are used for heart problems and blood pressure control.
It is not known if ranolazine extended-release tablet is safe and effective in children.
Who should not take ranolazine extended-release tablet?
Do not take ranolazine extended-release tablet if:
Before you take ranolazine extended-release tablet, tell your doctor if you:
Tell your doctor about all the medicines you take, including all prescription and nonprescription medicines, vitamins, and herbal supplements. Ranolazine extended-release tablet may affect the way other medicines work and other medicines may affect how ranolazine extended-release tablet works.
Tell your doctor if you take medicines:
How should I take ranolazine extended-release tablet?
Ranolazine extended-release tablet may cause serious side effects, including:
These are not all the possible side effects of ranolazine extended-release tablet. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
How should I store ranolazine extended-release tablet?
Store ranolazine extended-release tablets between 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Keep ranolazine extended-release tablet and all medicines out of the reach of children.
General information about ranolazine extended-release tablet.
Medicines are sometimes prescribed for purposes other than those listed in the Patient Information. Do not use ranolazine extended-release tablet for a condition for which it was not prescribed. Do not give ranolazine extended-release tablet to other people, even if they have the same condition you have. It may harm them.
The Patient Information summarizes the most important information about ranolazine extended-release tablet. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ranolazine extended-release tablet that is written for health professionals.
For more information, call Viona Pharmaceuticals Inc. at 1-888-304-5011.
What is chronic angina?
Chronic angina means pain or discomfort in the chest, jaw, shoulder, back, or arm that keeps coming back. There are other possible signs and symptoms of angina including shortness of breath. Angina usually comes on when you are active or under stress. Chronic angina is a symptom of a heart problem called coronary heart disease (CHD), also known as coronary artery disease (CAD). When you have CHD, the blood vessels in your heart become stiff and narrow. Oxygen-rich blood cannot reach your heart muscle easily. Angina comes on when too little oxygen reaches your heart muscle.
What are the ingredients in ranolazine extended-release tablet?
Active ingredient: ranolazine
500 mg tablet: ferrosoferric oxide, hypromellose, iron oxide red, iron oxide yellow, magnesium stearate, methacrylic acid copolymer type C (contains polysorbate 80 and sodium lauryl sulfate), microcrystalline cellulose, polyethylene glycol, sodium hydroxide, titanium dioxide and talc.
1000 mg tablet: ferrosoferric oxide, hypromellose, iron oxide yellow, magnesium stearate, methacrylic acid copolymer type C (contains polysorbate 80 and sodium lauryl sulfate), microcrystalline cellulose, polyethylene glycol, sodium hydroxide, titanium dioxide and talc.
This Patient Information has been approved by the U.S. Food and Drug Administration.
All other trademarks referenced herein are the property of their respective owners.